RxDoctor Payments Data

Suneeta Naik, MD

Family Medicine · Universal City, TXNPI 1245276732

Payments from drug & device makers

$1,148in general payments, 2019–2025

Across 59 payments — averaging $19.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$269
  • Abbott$205
  • Novo Nordisk$170
  • AstraZeneca$107
  • AbbVie$101
  • Boehringer Ingelheim$66
  • plus $231 from 8 others

What the payments were for

  • Food & beverage$1,148100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,148 in reported general payments places this provider in the 60th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$184,453
Medicare patients
236
Services billed
2,274

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide40$65,085
JardianceEmpagliflozin24$38,555
FarxigaDapagliflozin Propanediol29$34,656
EliquisApixaban24$33,594
Tresiba Flextouch U-200Insulin Degludec17$23,810
XareltoRivaroxaban24$23,466
TrulicityDulaglutide11$10,197
LinzessLinaclotide12$8,961
Rosuvastatin Calcium351$3,863
Atorvastatin Calcium189$2,127
Pantoprazole Sodium173$2,012
Nebivolol Hcl26$1,498
Levothyroxine Sodium129$1,449
Amlodipine-OlmesartanAmlodipine Bes/Olmesartan Med19$1,230
Olmesartan Medoxomil34$1,222

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$170$65,08540 claims
Boehringer IngelheimJardiance$66$38,55524 claims
AstraZenecaFarxiga$107$34,65629 claims
PfizerEliquis$48$33,59424 claims
Johnson & JohnsonXarelto$48$23,46624 claims
Lilly USA, LLCTrulicity$269$10,19711 claims
AbbVieLinzess, Synthroid$101$9,64828 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Universal City

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →